Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:MTAC NASDAQ:OPGN NASDAQ:SY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$3.15-0.6%$2.61$1.28▼$7.85$348.34M1.362.20 million shs1.55 million shsMTACMedTech Acquisition$11.34$10.79$8.43▼$12.83$83.80M-0.049,656 shs183,276 shsOPGNOpGen$1.61$0.00▼$0.00$1K-1.77477 shsN/ASYSo-Young International$3.08-4.3%$3.87$0.66▼$6.28$323.70M1.91816,426 shs1.31 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-0.63%+1.61%+25.00%+35.78%-58.66%MTACMedTech Acquisition0.00%0.00%0.00%0.00%0.00%OPGNOpGen0.00%0.00%0.00%-100.00%-99.99%SYSo-Young International-4.35%-8.61%-21.63%-47.53%-79.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$3.15-0.6%$2.61$1.28▼$7.85$348.34M1.362.20 million shs1.55 million shsMTACMedTech Acquisition$11.34$10.79$8.43▼$12.83$83.80M-0.049,656 shs183,276 shsOPGNOpGen$1.61$0.00▼$0.00$1K-1.77477 shsN/ASYSo-Young International$3.08-4.3%$3.87$0.66▼$6.28$323.70M1.91816,426 shs1.31 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-0.63%+1.61%+25.00%+35.78%-58.66%MTACMedTech Acquisition0.00%0.00%0.00%0.00%0.00%OPGNOpGen0.00%0.00%0.00%-100.00%-99.99%SYSo-Young International-4.35%-8.61%-21.63%-47.53%-79.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.40Hold$12.50296.83% UpsideMTACMedTech Acquisition 0.00N/AN/AN/AOPGNOpGen 0.00N/AN/AN/ASYSo-Young International 2.00Hold$5.5078.57% UpsideCurrent Analyst Ratings BreakdownLatest MTAC, OPGN, SY, and ANNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ANNXAnnexonWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SYSo-Young InternationalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025ANNXAnnexonWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SYSo-Young InternationalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)8/18/2025ANNXAnnexonZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/15/2025ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$2.75 per shareN/AMTACMedTech AcquisitionN/AN/A$0.89 per share12.80($2.04) per shareN/AOPGNOpGen$2.67M0.00N/AN/A($11.55) per share0.00SYSo-Young International$200.94M1.54$0.01 per share279.08$2.63 per share1.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$138.20M-$1.29N/AN/AN/AN/A-70.04%-57.67%11/13/2025 (Estimated)MTACMedTech Acquisition$5.54MN/A0.00∞N/AN/A-17.92%-1.48%N/AOPGNOpGen-$32.67MN/A0.00N/AN/A-1,140.36%N/A-287.58%11/13/2025 (Estimated)SYSo-Young International-$80.76M-$0.87N/A∞N/A-45.56%-4.96%-3.62%11/19/2025 (Estimated)Latest MTAC, OPGN, SY, and ANNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025ANNXAnnexon-$0.34N/AN/AN/AN/AN/A8/14/2025Q2 2025ANNXAnnexon-$0.36-$0.34+$0.02-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AMTACMedTech AcquisitionN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/ASYSo-Young InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A5.675.67MTACMedTech AcquisitionN/A0.030.03OPGNOpGenN/A5.455.45SYSo-Young InternationalN/A2.552.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AMTACMedTech Acquisition20.96%OPGNOpGen2.68%SYSo-Young International35.31%Insider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%MTACMedTech Acquisition76.20%OPGNOpGen43.80%SYSo-Young International16.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.89 million96.84 millionOptionableMTACMedTech Acquisition37.39 million1.95 millionNot OptionableOPGNOpGen10010.07 million4.70 millionNot OptionableSYSo-Young International1,800100.53 million83.74 millionNot OptionableMTAC, OPGN, SY, and ANNX HeadlinesRecent News About These CompaniesSo-Young International's (SY) Sell (D+) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comSo-Young: Turning Positive On Sales Beat And Attractive Valuations (Rating Upgrade)August 19, 2025 | seekingalpha.comSo-Young International Inc. (NASDAQ:SY) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comSo-Young International Reports Q2 2025 Financial Results Amid Strategic ExpansionAugust 15, 2025 | msn.comSo-Young (SY) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | fool.comSo-Young International Inc. (SY) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | seekingalpha.comSo-Young Reports Unaudited Second Quarter 2025 Financial ResultsAugust 15, 2025 | prnewswire.comSo-Young to Report Second Quarter 2025 Financial Results on August 15, 2025July 28, 2025 | prnewswire.comTop 2 Tech & Telecom Stocks That May Keep You Up At Night This MonthJuly 15, 2025 | benzinga.comCitigroup Upgrades So-Young International Inc. - Depositary Receipt () (SY)July 9, 2025 | msn.comSo-Young International Inc. ADR (SY) Stock Price Today - WSJJuly 8, 2025 | wsj.comSo-Young ADRs Whipsawed After Regaining of Nasdaq ComplianceJuly 4, 2025 | marketwatch.comSo-Young Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 3, 2025 | prnewswire.comSY So-Young International Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comSo-Young International Inc.: So-Young Announces Extension of Plan to Implement ADS Ratio ChangeJune 20, 2025 | finanznachrichten.deSo-Young Announces Extension of Plan to Implement ADS Ratio ChangeJune 20, 2025 | prnewswire.comSo-Young announces plan to implement ADS ratio change, shares downMay 30, 2025 | msn.comSo-Young Announces Plan to Implement ADS Ratio ChangeMay 30, 2025 | prnewswire.comSo-Young International Inc. (NASDAQ:SY) Q1 2025 Earnings Call TranscriptMay 20, 2025 | insidermonkey.comQ1 2025 So-Young International Inc Earnings CallMay 17, 2025 | finance.yahoo.comSo-Young International reports Q1 revenue decline, shares edge lowerMay 16, 2025 | in.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCarmax: Now is the Time to Load Up On This Used Car StockBy Thomas Hughes | September 26, 2025Can Advantage2 Help Overcome D-Wave's Share Price Plateau?By Nathan Reiff | September 18, 20253 Stocks Using Buybacks to Drive Sustainable Price GrowthBy Thomas Hughes | October 3, 2025Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer DealBy Leo Miller | October 6, 2025Coming in Hot: Retail Data Drives Momentum in 3 E-Commerce StocksBy Gabriel Osorio-Mazilli | September 20, 2025MTAC, OPGN, SY, and ANNX Company DescriptionsAnnexon NASDAQ:ANNX$3.15 -0.02 (-0.63%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$3.22 +0.08 (+2.38%) As of 10/17/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.MedTech Acquisition NASDAQ:MTACMedTech Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare sector in the United States. The company was incorporated in 2020 and is based in Greenwich, Connecticut. MedTech Acquisition Corporation operates as a subsidiary of Medtech Acquisition Sponsor LLC.OpGen NASDAQ:OPGNOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.So-Young International NASDAQ:SY$3.08 -0.14 (-4.35%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$3.11 +0.03 (+0.97%) As of 10/17/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.So-Young International Inc. operates an online platform for consumption healthcare services in the People's Republic of China. The company offers So-Young Mobile App that offers users medical aesthetic knowledge and experience to reach an informed medical aesthetic treatment decision and make reservations for treatment with medical professionals and medical aesthetic institutions; So-Young Beauty which provides similar interfaces and functions as the mobile app, as well as serves as additional access points to the platform; and medical aesthetic community content through its website soyoung.com. It provides content in various media formats on its online platform generated by users, including professional generated, content from in-house editorial team that shares opinions on specific new medical procedures and trends; user generated content comprising Beauty Diaries that provides details about medical institution, doctor, price, and other information on the treatment; professional user generated, contents from the medical aesthetic influencers; and doctor generated, content from doctors to generate knowledge. In addition, the company offers consumption healthcare services, including dermatology, dentistry and orthodontics, physical examinations, gynecology, and postnatal care; reservation services; and software as a service. Further, it engages in research and development, production, sales, and agency of laser and other optoelectronic medical beauty equipment; manufacture and sells light therapy device, surgical laser device and other equipment; internet information and technology advisory; online medical treatment and consultation; management consulting; internet culture; micro finance services, as well as sells cosmetics products. The company was founded in 2013 and is headquartered in Beijing, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
